Search

Your search keyword '"Minařík, Jiří"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Minařík, Jiří" Remove constraint Author: "Minařík, Jiří" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
40 results on '"Minařík, Jiří"'

Search Results

1. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

2. Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma

5. Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

6. Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

7. Retinal oxygen saturation in monoclonal gammopathies patients: A pilot study.

8. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

9. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

10. Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

15. Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients

18. Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

19. Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease

26. Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population

27. Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients

33. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)

36. Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic

37. Bortezomib (Velcade) in the Treatment of Relapsed or Refractory Multiple Myeloma: Analysis of Safety and Efficacy of Bortezomib From Registry of Monoclonal Gammopathy of Czech Myeloma Group

39. Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation.

Catalog

Books, media, physical & digital resources